Evidence map›Paper›PMID 38311623›Full record

ReviewSignal transduction and targeted therapy2024

Extracellular vesicles as tools and targets in therapy for diseases.

Mudasir A Kumar, Sadaf K Baba, Hana Q Sadida, Sara Al Marzooqi, Jayakumar Jerobin, Faisal H Altemani, Naseh Algehainy, Mohammad A Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 860 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
860citing papers in PubMed, 2 pooled it
224.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

860 citing papers in PubMed, 2 syntheses or guidelines pooled it, 959 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

800 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Mudasir A KumarWatson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Kashmir, 192122, India.
Sadaf K BabaWatson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Kashmir, 192122, India.
Hana Q SadidaDepartment of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.
Sara Al MarzooqiDepartment of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.
Jayakumar JerobinQatar Metabolic Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Faisal H AltemaniDepartment of Medical Laboratory Technology, Prince Fahad Bin Sultan Chair for Biomedical Research, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Naseh AlgehainyDepartment of Medical Laboratory Technology, Prince Fahad Bin Sultan Chair for Biomedical Research, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Mohammad A AlanaziDepartment of Medical Laboratory Technology, Prince Fahad Bin Sultan Chair for Biomedical Research, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Abdul-Badi Abou-SamraQatar Metabolic Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Rakesh KumarSchool of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.
Ammira S Al-Shabeeb AkilDepartment of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.
Muzafar A MachaWatson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Kashmir, 192122, India.ORCID 0000-0003-4468-4435
Rashid MirDepartment of Medical Laboratory Technology, Prince Fahad Bin Sultan Chair for Biomedical Research, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia. rashidmirtabuk@gmail.com.
Ajaz A BhatDepartment of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar. abhat@sidra.org.ORCID 0000-0003-3640-6275
Islamic University of Science and Technology · INUniversity of Tabuk · SAHamad Medical Corporation · QAFahd bin Sultan University · SAQatar Airways (Qatar) · QAShri Mata Vaishno Devi University · IN

Funding

Department of Biotechnology, Ministry of Science and Technology (DBT) D.O. NO.BT/HRD/35/02/2006
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are nano-sized, membranous structures secreted into the extracellular space. They exhibit diverse sizes, contents, and surface markers and are ubiquitously released from cells under normal and pathological conditions. Human serum is a rich source of these EVs, though their isolation from serum proteins and non-EV lipid particles poses challenges. These vesicles transport various cellular components such as proteins, mRNAs, miRNAs, DNA, and lipids across distances, influencing numerous physiological and pathological events, including those within the tumor microenvironment (TME). Their pivotal roles in cellular communication make EVs promising candidates for therapeutic agents, drug delivery systems, and disease biomarkers. Especially in cancer diagnostics, EV detection can pave the way for early identification and offers potential as diagnostic biomarkers. Moreover, various EV subtypes are emerging as targeted drug delivery tools, highlighting their potential clinical significance. The need for non-invasive biomarkers to monitor biological processes for diagnostic and therapeutic purposes remains unfulfilled. Tapping into the unique composition of EVs could unlock advanced diagnostic and therapeutic avenues in the future. In this review, we discuss in detail the roles of EVs across various conditions, including cancers (encompassing head and neck, lung, gastric, breast, and hepatocellular carcinoma), neurodegenerative disorders, diabetes, viral infections, autoimmune and renal diseases, emphasizing the potential advancements in molecular diagnostics and drug delivery.

Indexed as

Extracellular VesiclesMicroRNAsNeoplasmsVirus DiseasesBiomarkersHumansTumor MicroenvironmentBiomarkersMicroRNAs

Identifiers

PMID38311623
PMCPMC10838959
OpenAlexW4392737580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.